The new art of managing diarrhea-predominant IBS (IBS-D)…

Targets multiple factors

  • Small-bowel mucosal permeability and mucosal immune activation have been identified as factors typically associated with IBS-D5
    • There is evidence that low-grade inflammation plays a key role in IBS-related enteropathy—and that mast cell activation may be an important factor 6-8
    • Mast cells are in close proximity to intestinal neurons, and studies demonstrate that mast cell mediators may influence intestinal motility in IBS6-8

New EnteraGam™ manages mucosal permeability and immune activation.
Important Safety Information: The most commonly reported adverse events in clinical studies (incidence of 2–5%) included mild nausea, constipation, stomach cramps, headache, and increased urination.
Please see full Important Safety Information in Safety section and
full Prescribing Information including contraindications in PI section.